BioXcel Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2017 to 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
BioXcel Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2024.
  • BioXcel Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$10.5M, a 47.2% increase year-over-year.
  • BioXcel Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$67.2M, a 60.9% increase year-over-year.
  • BioXcel Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$67.2M, a 60.9% increase from 2023.
  • BioXcel Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$172M, a 7.6% decline from 2022.
  • BioXcel Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$160M, a 49.3% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$67.2M +$105M +60.9% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-28
2023 -$172M -$12.1M -7.6% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-28
2022 -$160M -$52.7M -49.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-22
2021 -$107M -$24.6M -29.9% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-16
2020 -$82.3M -$48.7M -145% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-11
2019 -$33.6M -$13.6M -68.3% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-12
2018 -$20M -$15.4M -340% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-09
2017 -$4.54M Jan 1, 2017 Dec 31, 2017 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.